

Study of Radiotherapy with NOX66 in patients with late-stage Prostate Cancer open for Recruitment in Australia.

The DARRT-1 Study (NOX66-002A) – is now open for recruitment. The study is enrolling patients with late stage, metastatic prostate cancer who are suitable for palliative (short duration) radiotherapy as part of patient care. Further information regarding the trial is available on the clinicaltrials.gov website (click <u>here</u> for access). Sites are currently open in Newcastle, NSW and Gold Coast, Queensland with further sites in Sydney and regional areas of NSW opening over the coming weeks.

If you are interested in participating in the study, please contact : medical.information@noxopharm.com